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Abstract: The present article reviews the clinical use of thiol-based metal chelators in intoxications
and overexposure with mercury (Hg), cadmium (Cd), and lead (Pb). Currently, very few commercially
available pharmaceuticals can successfully reduce or prevent the toxicity of these metals. The metal
chelator meso-2,3-dimercaptosuccinic acid (DMSA) is considerably less toxic than the classical agent
British anti-Lewisite (BAL, 2,3-dimercaptopropanol) and is the recommended agent in poisonings
with Pb and organic Hg. Its toxicity is also lower than that of DMPS (dimercaptopropane sulfonate),
although DMPS is the recommended agent in acute poisonings with Hg salts. It is suggested that
intracellular Cd deposits and cerebral deposits of inorganic Hg, to some extent, can be mobilized by a
combination of antidotes, but clinical experience with such combinations are lacking. Alpha-lipoic
acid (α-LA) has been suggested for toxic metal detoxification but is not considered a drug of choice in
clinical practice. The molecular mechanisms and chemical equilibria of complex formation of the
chelators with the metal ions Hg2+, Cd2+, and Pb2+ are reviewed since insight into these reactions
can provide a basis for further development of therapeutics.
Keywords: BAL; DMPS; DMSA; metal chelator; metal ion
1. Introduction
The US Agency for Toxic Substances and Disease Registry assembles a list of the substances that
can cause the most significant problems to human health for their toxicity and potential for human
exposure. It should be noticed that this priority list is not a list of “the most toxic” substances, but
rather a prioritization of substances based on a combination of their frequency, toxicity, and potential
for human exposure. This list is regularly revised to take into account any new information on toxic
substances [1].
On these bases, lead (Pb), mercury (Hg), and cadmium (Cd) are classified not only as the most
relevant toxic metals, but also as the most relevant toxic substances in general. Furthermore, the World
Health Organization (WHO) has also included these three toxic metals in the top 10 chemicals of major
public health concern [2].
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Therefore, in the present review, we will take into consideration the chelating agents that can be
useful for the clinical treatment of Pb, Hg, and Cd intoxication. In particular, since the sulfhydryl (SH)
groups of proteins furnish the vehicle for both the toxicity and detoxification of the majority of heavy
metal ions, we will take into consideration chelating agents characterized by thiol groups. The review
aims to delineate principles that can be used in the search for improved antidotal treatments of these
three toxic metals. We will start by recalling the hard–soft properties of these metal ions [3] reported in
Table 1.
Table 1. Classification of the toxic metals, and the coordinating groups, according to their hard,
intermediate (borderline), and soft character. The implied metal ions and coordinating groups are
marked in red.
Metal Ions Coordinating Groups
Hard Borderline Soft Hard Borderline Soft
Li+, Na+, K+, Be2+
Mg2+, Ca2+, Sr2+,
Mn2+, Al3+, Ga3+,
Cr3+, Fe3+, Sn4+,
(CH3)2Sn2+,
UO22+, VO2+
Fe2+, Co2+,
Ni2+,
Cu2+, Zn2+,
Pb2+,
Sn2+, Sb3+, Bi3+
Cu+, Ag+, Au+,
Hg+, Pd2+,
Cd2+,
Pt2+, Hg2+,
CH3Hg+, Pt4+
H2O, OH−, F−,
RCOO−, Cl−,
RO−, NH3,
RNH2
C6H5NH2 R2S,
RSH,
RS−
It can be observed that Cd2+ and Hg2+, both belonging to group 12 in the periodic table of
elements, are classified as soft metal ions, preferring the coordination by ligands characterized by
soft groups such as R2S, RSH, and RS [4]. On the other hand, Pb2+, which belongs to group 14 in the
periodic table, is classified as an intermediate metal ion, indicating that above all it will be coordinated
by amino groups, even if the interaction with hard oxygen groups and soft thiol groups is observed
in a number of complexes. Furthermore, different structural coordination modes characterize these
metal ions, such as linear coordination for Hg with thiol groups, or tetrahedral for Cd, but these
considerations will be further developed in the last sections of the present paper.
2. Exposure and Effects
Table 2 reports some exposure sources and target organs for Hg, Cd, and Pb, which will be
discussed in the following lines.
Table 2. Some exposure sources and target organs for Hg, Cd, and Pb.
Important Sources of
Occupational
Exposure
Routes of
Exposure
Important Sources
of Environmental
Exposure
Routes of
Exposure
Target Organs of
Toxicity
Elemental
mercury
Coal-burning, waste
incineration, gold
extraction, dental
amalgam handling,
fluorescent lamp
manufacturing
Inhalation Dental amalgam in
teeth
Inhalation Central and
peripheral nervous
system
Inorganic
mercury salts
- - Use of skin
lightening
products and
medicinal use of
mercury salts
Gastrointestinal
ingestion,
transdermal
Kidneys
Methyl
mercury
- - Food (fish,
seafood)
Gastrointestinal
ingestion
Central nervous
system
Cadmium Production of
nickel-Cd batteries, Cd
plating, Cd-containing
paint production
Inhalation Food (rice, potato,
and wheat, offal,
seafood)
Tobacco smoke
Gastrointestinal
ingestion
Inhalation
Kidneys
Skeleton
Lead Mining, smelting,
battery manufacturing,
traditional printing
technology
Inhalation Food, drinking
water,
dust and soil (in
children)
Gastrointestinal
ingestion
Central nervous
system,
hematopoietic
system, kidneys
Molecules 2019, 24, 3247 3 of 32
2.1. Mercury
Environmental Hg exists in three chemical forms, viz. elemental Hg (metallic Hg0 liquid),
inorganic mercuric salts (e.g., Hg chloride, HgCl2), and organic Hg compounds (e.g., methylmercury
(MeHg, CH3Hg) and ethylmercury (EtHg, C2H5Hg)) [5,6]. Humans are exposed to low chronic levels
of mercurial compounds via various routes: Oral, inhalation, and dermal [7], to MeHg mainly through
fish, Hg vapor from dental amalgams, and EtHg through vaccines [8].
Although organic Hg is regarded as the most frequent and toxic one, elemental Hg is more volatile
and, hence, more dangerous than generally perceived. Elemental Hg0 exists as liquid metal and can
vaporize at room temperature due to high vapor pressure. For example, a worker who stays for about
eight hours in a Hg-saturated place can inhale up to about 100 mg of Hg per day [9]. Major sources of
elemental Hg emissions to the air are coal burning, metal smelting, crematoriums, waste incineration,
and small-scale gold extraction [10]. Emitted Hg vapor is oxidized to ionic form (Hg2+) in the air layers,
which falls to the ground with rain, often far from the emission point. This makes Hg exposure a global
concern. In the soil layers and sediments, Hg has a very long half-life [11,12]. Also, Hg occurs naturally
as a result of volcanic activities, forest fire, water movement, etc. [13]. Other important sources of
Hg exposure is the use of Hg in measuring instruments and as a disinfectant. Regulatory measures
during the last decades have reduced the Hg emissions to the environment significantly [12]. However,
still, some hot spots of Hg pollution exist. Mainly in developing countries, Hg poses a threat to the
environment and health of nearby living residents. Hence, environmental and human Hg exposure
assessments are needed in these regions [11].
The main sources of elemental Hg in humans are Hg released from dental amalgams batteries,
and incineration of medical waste [14,15]. In the 1830s, dental amalgam was introduced in the
Western World and has since then been subject to recurrent concerns and controversies [16]. Today,
many countries, including the Scandinavian countries and Italy, have in principle ceased the use of
dental amalgam. However, this filling material is still in widespread use, particularly in developing
countries [14].
Elemental Hg is oxidized to divalent inorganic Hg in red blood cells and tissues [17]. However,
some Hg vapor passes the blood–brain barrier and enters the brain. Elemental Hg, which is highly
diffusible and lipid-soluble, is oxidized and accumulated in the human brain. Its half-life in the brain
is several years to several decades [18]. Numerous toxic effects and conditions have been linked to Hg
vapor exposure. It has been suggested that inhaled Hg vapor from amalgam fillings is a predisposing
factor to Alzheimer’s disease [19]. However, this hypothesis remains to be verified [20]. Research
has also shown that Hg vapor passes the placenta and is taken up by the fetus. The inorganic Hg
concentrations in the placenta and umbilical cord have been found to correlate with the mother’s
number of amalgam fillings [21,22]. Dental personnel who are occupationally exposed to Hg have
a higher Hg body burden than unexposed individuals., Recently this was reviewed by Aaseth et
al. [23] and Bjørklund et al. [24]. Also, dental personnel more often develop uncharacterized symptoms
like fatigue, weakness, and anorexia than unexposed people [23]. A similar trend was shown for
neurobehavioral effects, like idiopathic disturbances in cognitive skills, affective reactions, and motor
functions [24].
In addition to dental personnel, occupational Hg exposure also occurs in the chloralkali industry
(if Hg electrodes are used) and in the manufacture of fluorescent lamps and batteries. Adverse effects in
the central nervous system of chloralkali workers may persist for ten years or more after high Hg vapor
exposure has ceased. Mathiesen et al. [25] found that a group of 70 previously H-exposed chloralkali
workers (time passed after the last exposure was on average 12.7 years) had decreased performance
on a number of neuropsychological tests compared to an unexposed control group of 52 workers.
Comparable results were shown in another study of high-level Hg vapor-exposed workers [26]. It
has been demonstrated that adverse Hg effects in the peripheral nervous system are detectable even
decades after cessation of exposure [27]. The major clinical feature of chronic elemental Hg poisoning
is a triad of tremors, erethism, and gingivitis [28]. Long-term chronic Hg vapor exposure led to
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mercurial erethism, characterized by excessive shyness and social phobia [29]. In the 19th century,
mercuric nitrate was commonly used in felt hat production. At that time in England and the US, the
syndrome of erethism was common among exposed hatters. More on historical perspectives of Hg
poisoning is given by Brooks et al. and Buckell et al. [30,31]. Apart from the central nervous system
toxicity, elemental Hg can affect the human immune system or cause toxic pulmonary, reproductive, or
cardiovascular effects [15].
Inorganic Hg2+ is absorbed from the gastrointestinal tract after ingestion and also through the
skin [32]. The highest inorganic Hg levels are found in kidneys. In the kidneys, inorganic Hg
can give many effects, including proteinuria and polyuria. This can further progress into nephritic
syndrome [33]. Chronic inorganic Hg poisoning can also cause acrodynia, which is considered a
hypersensitivity reaction, characterized by profuse sweating and erythematous rashes of the palms
and soles [32].
Of serious concern is Hg exposure via fish and seafood. Mercury bioaccumulates and biomagnifies
in the food chain, after biomethylation to MeHg [11,13]. Usually, the MeHg levels increase with
the age of the fish [34]. Methylmercury has caused major environmental disasters [35]; the most
serious happened in Minamata Bay, in Japan. In the 1950s, the plastic plant belonging to the Chisso
Corporation group emitted wastewater containing Hg into this sea bay [36,37]. Over time, this
caused a massive Hg accumulation in the food chain. Minamata disease is a neurological syndrome
encompassing symptoms of sensory disturbances, ataxia, dysarthria, constriction of the visual field,
auditory disturbances, and tremor. Another poisoning incident happened 20 years later in Iraq when
the sensory, motor and visual disturbance were developed after ingestion of bread contaminated with
organomercury fungicide [38]. After ingestion and rapid absorption of MeHg in the gastrointestinal
tract, it circulates in the blood bound to SH-containing amino acid residues and distributed to the
central nervous system and other parts of the organism [39,40]. By the use of molecular mimicry,
MeHg, bound to the SH group of cysteine, crosses the blood–brain barrier and arrives at glial cells and
neurons, where it is slowly converted to inorganic Hg [41]. Epidemiological studies have shown that
pregnant women who are exposed to large MeHg concentrations give birth to children with severe
brain damage even without having any poisoning symptoms themselves [11,42]. Furthermore, MeHg
has been implicated in many neurodegenerative diseases, and a possible role in autism spectrum
disorder has been suggested [20,41,43].
According to the International Agency for Research on Cancer, MeHg compounds are possibly
carcinogenic to humans (group 2B), while metallic Hg and inorganic Hg compounds are not considered
carcinogenic to humans [44].
Mercury compounds exert toxic actions through various mechanisms. Research indicates that
toxic effects of organic Hg in the nervous system may be caused or worsened by the oxidized form,
Hg2+, that binds to the thiol (-SH) groups and thereby alters protein structure and/or inhibits enzymatic
functions [41]. Numerous studies have also suggested other mechanisms of Hg toxicity such as
induction of oxidative stress, damage of Ca homeostasis, and changes in glutamate homeostasis [6].
2.2. Cadmium
Metallic Cd is, to a significant extent, a by-product of zinc (Zn) production and to some degree,
also a by-product from copper (Cu) and Pb production [45]. Since 1990, the annual use of Cd is about
20,000 tons worldwide. Recycling accounts for ca. 18% of the production. A majority of Cd is used in
nickel-Cd batteries. Also, Cd is used for corrosion protection of steel (cadmium plating), as a solder
and weld metal in alloys, in polyvinyl chloride plastics, and as a pigment in paint colors, different
types of paint, and glazes [46].
Numerous studies have reported health effects of Cd exposure in the general population, even in
subjects without particular industrial exposure. The estimated Cd exposure in many areas, particularly
industrial ones, is high enough to represent a human health threat [47–49]. Environmental Cd
contamination is mainly a result of anthropogenic activities, but can also be of natural origin [50]. Due
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to high rate soil-to-plant transfer, Cd enters and accumulates in the food chain [51]. In most parts of
the world, food is the primary Cd source for non-smokers [47].
Foods rich in Cd include offal, seafood, cocoa powder, and wild mushrooms. However, due to
the larger consumption, 80% of Cd in food comes from staples (rice, potato, and wheat) [52,53]. The
average daily Cd intake from food is 8–25 µg [50,52]. Currently, the Food and Agriculture Organization
(FAO) and World Health Organization (WHO) Joint Expert Committee on Food Additives and
Contaminants consider 25 µg Cd per kg body weight/month as a tolerable intake level [54]. However,
certain subpopulations can have a much higher Cd intake than the average population (vegetarians,
populations that consume rice as a dominant energy source) [52]. Tobacco leaves accumulate Cd.
Therefore, cigarette smoke is a significant Cd source in the general population [55]. Cadmium in
drinking water typically only contributes a few percent of the total Cd intake [53]. In the air, Cd is
present in trace amounts [56]. Therefore, exposure from air generally provides less than a few percent
of the total Cd body burden. However, Cd-polluted water and air and even house dust may occur in
areas close to some metal industries. Itai-itai disease is the documented case of a mass Cd poisoning in
Toyama Prefecture, Japan. What became the world’s first large Cd poisoning disaster started around
1912 and caused a crippling and very painful form of osteomalacia including severe kidney damage
and multiple bone fractures [57] The disease got its name due to the pain moans.
After Cd uptake in the body, it is transported via the hepatic portal system to the liver, where Cd
induces synthesis of metal-binding proteins, metallothioneins (MTs). Inhaled Cd induces MTs in the
lungs, where CdMT complexes are formed directly. CdMTs are released from the liver, enterocytes,
and lungs into the systematic circulation. Thus, Cd is transported primarily to the kidneys where it
accumulates. A recent review by Satarug presents a detailed overview of Cd kinetics [51]. The half-life
of renal Cd is 7–16 years [58] or longer [59]. However, the accumulation of Cd in the organism varies
with age, gender, smoking status, and certain co-morbidities.
Long-term Cd exposure affects many organs. The kidneys have been considered the critical organ
of Cd toxicity. Even low-level, long-term Cd exposure may induce various kidney dysfunctions [60].
Also, the liver is critical to Cd accumulation. In both sexes, both acute and chronic Cd exposure is
linked to various liver-related diseases [60,61]. Recent epidemiological studies confirm the association
between Cd exposure and increased risk of osteoporosis-related fractures [62], which originally
was observed during the Itai-itai epidemic in Japan. Also, associations between Cd exposure and
cardiovascular diseases [63], reproductive disorders in both sexes [64–66], thyroid disorders [67],
gestational diabetes, and diabetes mellitus type 2 [68,69] have been shown. Also, Cd may produce
hormesis phenomena [70]. IARC classifies Cd and Cd compounds as known human carcinogens [44],
based on a causal relationship between exposure and lung cancer. New research has also shown
positive associations between chronic Cd exposure and kidney and prostate cancers [71]. Studies have
implied a possible role of Cd in pancreatic [72,73], bladder [74], prostate [75], and breast cancer [76].
The mechanisms of Cd toxicity are various and include binding to SH groups, oxidative stress
induction [77,78], interactions with bioelements [79–82], mitochondrial toxicity [83], and altered
microRNA expression [84].
2.3. Lead
For several decades, the use of Pb-containing gasoline was an environmental and human exposure
source of organic Pb compounds [85,86]. Since the 1920s, Pb usually added as tetraethyl lead (TEL) to
gasoline caused significant exposure via inhalation of car exhaust [87]. Since Pb is toxic, this gasoline
was gradually phased out in most countries of the world. In the US, Pb in gasoline was banned from
1996, and in the EU, organolead was entirely phased out in 2000 [87]. The removal of Pb from gasoline
is regarded as one of the major public health triumphs of the 20th century. Also, much work has been
done to phase out Pb from various other products completely. To completely eliminate Pb from gasoline
and water pipes took a long time but effectively reduced Pb pollution in the environment [86,88].
However, due to the persistence of Pb, it is still present in the environment. Although food generally
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contains low Pb levels, most of the Pb exposure in many countries nowadays occurs through food
and drinking water [86,89]. In Europe, the average exposure via diet is about 0.50 µg Pb/kg body
weight/day [90]. Cereal products contribute most to dietary Pb exposure, while Pb in dust and soil
can be important sources for children. Also, Pb in old paint dust and soil can be a source of increased
Pb exposure for small children, due to their tendency for licking, chewing, and swallowing foreign
bodies [91,92]. Residual paints that contain significant quantities of Pb is a problem in many countries
of the world, especially for children [93].
Lead exposure mainly happens through the gastrointestinal and respiratory tract. Approximately
30%–40% of Pb from the respiratory tract is absorbed into the bloodstream while the gastrointestinal
absorption depends mainly on age and nutritional status [86,94]. Hence, while adults absorb around
10%–15% of ingested Pb, this amount increases up to 50% in infants, young children, and pregnant
woman [85,94,95]. Once absorbed, Pb is transported by the bloodstream mainly bound to erythrocytes
and distributed to other tissues such as liver, kidneys, brain, lungs, spleen, teeth, and bones. More
than 95% of Pb is deposited in skeletal bones while in children, this percentage is less resulting in more
Pb in soft tissues [85,86]. Furthermore, Pb passes the placental barrier during pregnancy and can cause
damage to the fetus. Concentrations of Pb found in the umbilical cord blood are 80%–100% of the
maternal blood levels [96].
Toxic effects of Pb have been detected in virtually every body system. Children are generally
more vulnerable to Pb toxicity than adults, especially for neurological Pb toxicity. The most deleterious
effects of Pb are detected on erythropoiesis, kidney function, and the central nervous system [85,86,97].
Other toxic effects of Pb include hypertension and hearing impairment, infertility, abdominal pain
(“lead colic”), and anorexia [97]. Recent research has linked the level of Pb in drinking water to
increased risk of cardiovascular pathologies [98]. For children, Pb exposure may impair cognitive
abilities, attention, mental development, and skeletal growth [99]. Also, disturbed blood formation and
renal effects may occur in children at relatively low Pb exposure [100]. A lower threshold for children
that provides complete safety against Pb poisoning has not been established. The International Agency
for Cancer Research classified inorganic Pb as probably carcinogenic to humans (Group 2A) [101].
Many in vivo and in vitro studies have been performed to identify the exact mechanisms of Pb
toxicity. Some of them are oxidative stress induction [77,102], binding to sulfur ligands that can affect
many enzymes and proteins [77], interaction with bioelements [102], changes in DNA structure, and
inhibition of DNA repair [103].
3. Endogenous Protective SH-Compounds: Metallothioneins and Glutathione
3.1. Metallothioneins (MTs)
The metallothionein (MT) family is cysteine-rich and consists of proteins with low molecular
weight (mol. wt. ranging from about 1000 to 14,000 kDa). They are localized intracellularly and can
bind both essential and non-essential heavy metals, e.g., Zn, Cu, Cd, Hg, silver (Ag), and As, through
the thiol group of its cysteine residues. Approximately 30% of the amino acids in MTs are cysteine.
MTs are found in yeasts, plants, invertebrates, as well as vertebrates including humans.
Margoshes and Vallee [104] discovered MT when they purified a Cd-binding protein from the
renal cortex of horses. Still, the MTs functions are not entirely understood, but apparently, they protect
against the effects of toxic metals as well as being involved in the physiological regulation of Cu and
Zn. MTs also protect against oxidative stress [105]. In principle, four isoforms of MTs are present
in humans (i.e., MT1 with subtypes, MT2, MT3, and MT4) [106]. All isoforms contain polynuclear
metal-sulfur coordination sites. In mammals, MT1 and MT2 are the most common isoforms. In the
liver and also in the gut, these MTs get induced by many different metals, especially by Zn ions. MT3
has been found in the central nervous system, and MT4 has been found in epithelial cells. MT3 appears
to have a protective function against oxidative stress in the brain [107].
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For the production of MT1 and MT2 in the liver, dietary Cu and Zn, as well as the amino acids
cysteine and histidine, are needed. The content of the metals in MTs depends on their stability constants
and their amount in the body. MTs can tie up many different metals, including Cd, Zn, Hg, and Cu.
Through their binding and release of Zn, MTs can regulate the cellular levels of Zn. According
to their affinity constants with MTs, many toxic metal ions, including Hg2+, Cu+, Ag+, Cd2+, Bi2+,
and Pb2+, might displace Zn2+ from MT. The free Zn, in turn, plays a key role for the binding and
activation of transcription factors, especially the metal-regulatory transcription factor 1 (MTF-1), and
Zn release induces more MT being synthesized.
Residues of cysteine from MTs may also capture oxidant radicals, including the harmful hydroxyl
and superoxide radicals [108]. In such reactions, cysteine oxidizes to cystine, and the Zn ions that were
cysteine bound are disconnected. Released Zn can activate the synthesis of further MTs. Various factors
induce the gene expression of MTs, including metal exposure, oxidative stress, and glucocorticoids.
The MT gene controls the response level of these inducers. MTs can also carry Zn ions between different
parts of the cell. When Zn enters into a cell, thionein can take up the trace element and carry it to other
cellular parts. This kind of signaling system is considered of particular importance in the brain, where
Zn signaling appears crucial both within and between nerve cells [109].
3.2. Glutathione (GSH)
Glutathione (GSH), the tripeptideγ-glutamyl-cysteinyl-glycine, is a crucial antioxidant for animals,
plants, as well as for some bacteria, in preventing damage on essential cellular components due to
some metal ions and peroxides. GSH is the crucial intracellular reducing agent in animal cells. GSH is
biosynthesized in the body from its amino acid constituents. Its cysteine thiol group (SH) functions as
an electron donor in its interactions with metal ions or oxygen radicals. Cysteine is considered the
rate-limiting factor in cellular GSH biosynthesis due to its relatively little presence in foods. The cellular
biosynthesis of GSH involves two ATP-dependent steps: First, γ-glutamyl-cysteine is synthesized from
L-glutamate and cysteine through the action of the enzyme gamma-glutamyl-cysteine synthetase. This
initial step in the GSH synthesis is rate-limiting in the synthesis. In the second reaction, the enzyme
glutathione synthetase adds glycine to the γ-glutamylcysteine. GSH exists in two different states, i.e.,
both as oxidized (GSSG) and reduced (GSH) states. In its reduced state, a reducing equivalent (H++
e−) can be donated by the SH group to unstable molecules such as reactive oxygen species. When
an electron gets donated, a GSH molecule becomes reactive but reacts readily with another reactive
molecule of GSH to create glutathione disulfide (GSSG). Oxidized GSSG is reduced rapidly back to
GSH by glutathione reductase, in a reaction where NADPH is used as a donor of electrons [110].
Some important functions of GSH are as follows:
1. It is the principal endogenous antioxidant that the cells produce, it participates directly in the
neutralization of ROS and free radicals, and it is a cofactor of the selenoenzyme glutathione
peroxidase (GPx).
2. GSH is an important substrate for conjugation reactions, catalyzed by the glutathione-S-transferase
enzyme. Thus, in the case of the reactive metabolite formed by a paracetamol overdose, GSH
acts as an antidote. GSH can also conjugate and detoxify organometallic compounds, such as
MeHg [111].
3. It has important roles in binding, transport, and storing of several metals, thus affecting the
homeostasis of metals in biological systems [112].
Here, we will concentrate on its ability to bind toxic metals [113]. Among metals reported to bind
to GSH are Cu, Hg, Cd, and Pb. Metals bound by GSH can be exchanged with other ligands. This
leads to a fast metal redistribution in the body. The bile appears to be a main excretory pathway for
some metal–GSH complexes, which was early indicated for the CH3Hg–GSH conjugate. When GSH
reacts with a metal, there are two possible outcomes: The metal gets either stabilized as a nonreactive
conjugate or the metal, such as transition metals, can undergo a redox reaction paralleled by oxidation
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of GSH and formation of ROS. Most frequently, GSH binds to metals and protects against the toxicity,
e.g., of Hg2+.
In healthy tissue and cells, more than 90% of GSH exists in the reduced form (GSH), and less
than 10% exists in the disulfide form (GSSG). Increased GSSG/GSH ratio is considered indicative of
oxidative stress.
4. SH-Containing Chelating Agents: Clinical Use and Environmental Remediation
In 1920, Morgan and Drew suggested the term chelate [114], which originates from the Greek word
chele (claw of a lobster). The term was suggested to be used on the caliper-like groups that function
together as two units, which connect a central atom and create heterocyclic rings. In therapeutic
use, chelators remove metals from chemical compounds through the formation of complexes. An
excellent chelator should be characterized by high solubility in both lipids and water, resistance to
biotransformation, ability to reach the sites of metal storage, retain chelating ability at the pH of
body fluids, as well as being able to form metal complexes with lower toxicity than the free metal
ions [115–117]. Unfortunately, even today, most chelators are not able to cross the blood–brain barrier
and therefore have limited ability to remove the metals from the brain tissue [4,118].
For more than a century, chelating agents were used by Ehrlich and Werner to decrease the
toxicity of arsenic (As)-containing syphilis drugs. During 1920–1940, similar trials to reduce the
toxicity of antimony drugs for schistosomiasis and trypanosomiasis were done by Voegtlin et al. [119].
In 1941, Kety and Letonoff used citrate as an antidote towards acute Pb intoxication [120]. This
experiment started a new era in treating metal intoxications caused by environmental exposure or
genetic disturbances in metal metabolism.
During World War II, Sir Rudolph Peters and colleagues developed the antidote BAL (British
anti Lewisite) against the war gas dichlorovinyl arsine (Lewisite) [121]. The next chelator, EDTA
(ethylenediamine tetraacetate) was developed for radionuclide decorporation and clinical treatment of
Pb intoxication [122]. EDTA must be administered parenterally. Since the intestinal uptake it low, its
action is almost exclusively extracellular. To some essential metals, its stability constants are high.
During the 1950s, DMSA (meso-dimercaptosuccinic acid) and DMPS (2,3-dimercapto-1-
propanesulfonic acid) were used in China [123] and the former Soviet Union [124]. These drugs have
been available in the Western world for decades. DMSA is a registered drug in USA and DMPS in
Germany. Several decades passed until Western clinicians fully realized their value. Today, they are
first-line antidotes in acute or chronic intoxications with many divalent metal salts. The clinical use of
DMSA and DMPS in metal intoxications was reviewed by Aaseth [115] and Aposhian et al. [125].
Originally, BAL was a general antidote particularly used in acute As [126] and inorganic Hg
poisonings [127]. Earlier, alternative antidotes did not exist. However, BAL is not considered a
good chelator today due to its high toxicity. BAL can increase the deposition of Hg and As in
the brain [128]. DMSA and DMPS, which are less toxic, are suited for both oral and parenteral
administration. Previously, EDTA was used in childhood and occupational Pb intoxications. However,
it is no longer recommended due to a possible redistribution of Pb to the brain [129].
4.1. BAL (2,3 dimercaptopropan-1-ol)
BAL, which is a dithiol compound, was originally used to treat poisonings caused by the war
gas Lewisite [121]. It competes successfully with protein SH groups for the treatment of Lewisite and
other As poisonings. Also, BAL forms stable chelates with other toxic metals. For several decades
after World War II, it was recommended for inorganic Hg, arsenic, antimony, gold, and bismuth
poisonings [130]. In cases of elevated intracranial pressure and encephalopathy due to acute Pb
poisonings, BAL was earlier recommended given i.m. in the initial phase in combination with calcium
EDTA infusion [131]. However, this advice is now outdated [129]. BAL has a short half-life. Within
four hours, its metabolism and excretion are completed. Given in full dose, BAL has severe and
sometimes very serious adverse effects, including elevated blood pressure followed by tachycardia.
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Due to the high toxicity, BAL is currently only used for a few days in life-threatening and acute Pb or
As intoxications [132]. Due to BAL’s small safety margin, tendency to redistribute toxic elements to
the brain, and painful intramuscular injections, it is, in most cases of metal poisoning, replaced by
DMSA and DMPS [4]. In the few cases when BAL is used, it is given as deep intramuscularly injections
(2.5 mg BAL/kg every four hours). BAL is contraindicated in the treatment of poisonings with Cd, as
well as alkyl- and aryl-Hg compounds.
4.2. DMSA (meso-dimercaptosuccinic acid, Succimer)
DMSA (meso-dimercaptosuccinic acid, Succimer) and DMPS (2,3-dimercaptopropane-1-sulfonic
acid, Unitiol) are water-soluble dithiols, derived from dimercaprol (2,3-dimercapto-1-propanol,
BAL) [133].
DMSA can be administered as intravenous, oral, transdermal, or suppository preparations. Plasma
and whole-blood half-lives and urinary elimination half-life of DMSA are less than four hours in
humans [134,135]; longer in Hg-intoxicated persons [136]. Since DMSA is hydrophilic, it can be
administered orally. About 20% of it is absorbed in the gastrointestinal tract, depending on the gut’s
health status. About 95% of the absorbed drug bind to plasma proteins (albumin). It probably binds
by one of its SH groups on a cysteine residue of albumin. Thereby, DMSA leaves its other SH group
free to bind metals [137]. Of the free drug, only a tiny amount remains [135]. Only 10%–25% of the
oral application is excreted through urine. The other part is excreted via feces. In the body, it is largely
metabolized to various disulfides with cysteine [138–140]. DMSA is confined to the extracellular space
and does not enter red blood cells [134]. It increases the excretion of Ag, Cd, Pb, and Hg via the urine.
Also, it can remove MeHg and Pb from animal brains [141]. Children have a lower renal clearance for
DMSA than healthy adults [135].
DMSA is considered the drug of choice in organic Hg poisonings [130,142]. It does not pass
the blood–brain barrier but appears to indirectly reduce the MeHg brain burden by changing the
brain-to-blood equilibrium [129,141,143–145].
Compared to other dithiol antidotes, DMSA is less toxic [146]. It also has the advantage that
practically no essential metal is lost (Fe, Ca, magnesium (Mg)). Only minor changes in Cu metabolism
is observed [144]. Side effects range from skin reactions, mild neutropenia, and gastrointestinal
discomfort, to increased liver enzymes [138]. Rare adverse effects of DMSA treatment are toxic
epidermal necrosis and mucocutaneous eruptions [143,147].
In 1991, Roels et al. [148] found that intake of two grams DMSA significantly elevated urinary Hg
excretion in occupationally Hg-exposed people. A meta-analysis by Miller et al. [137] proved DMSA
safe and efficient. They concluded that DMSA, due to its efficacy, urinary Hg excretion, and safety, is
the preferred antidote against Pb. On average, oral DMSA treatment increases the excretion of Pb by a
factor of 12. In 17 Pb-poisoned adults, DMSA reversed the gastrointestinal and neurological symptoms
of Pb poisoning [140]. Excretion of Pb after DMSA administration increased significantly in chronically
exposed adults and children [130]. A patient reported by Gustavsson and Gerhardsson had severe
symptoms of Pb poisoning from an accidentally ingested Pb bullet during a game meal. Years after the
incident, the patient was cured after removal of the bullet from the bowel and over one year of therapy
with DMSA [149].
4.3. DMPS (2,3-dimercaptopropane-1-sulfonic acid, Unitiol)
In different countries, DMPS can be prescribed as a drug in capsules for oral antidote treatment
(one capsule Dimaval® contains 100 mg DMPS) or in ampoules for intravenous treatment (5 mL
ampoule DMPS-Heyl® contains 250 mg DMPS). In Germany, DMPS is a registered drug for treatments
of Hg intoxication. However, it is not an approved drug in the US, so unless the U.S. Food and Drug
Administration gives special permission, DMPS cannot be legally used by physicians in the US, nor
can pharmacies compound it [150]. The daily dose is usually 3–10 mg DMPS/kg body weight.
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Many studies have proven its efficiency to chelate toxic metals in the body [145]. DMPS is
considered an optimal antidote in inorganic Hg poisonings [130]. For Pb and organic Hg poisonings, it
is less efficient than DMSA [151].
The fraction of absorption of oral DMPS is less than 40% [152]. DMPS can be administered
orally or intravenously. DMPS converts quickly to disulfide form. The half-life in different organs for
DMPS is approximately 20 min [153]. In animal experiments, relatively small DMPS concentrations
were detected in the brain and other organs [144]. DMPS is primarily excreted via urine and to
some part via the bile. Its use is usually accompanied by some loss of Zn and Cu. Therefore, it is
recommended to monitor and replace these trace elements before and after the treatment [154]. DMPS,
which is hydrophilic, is distributed primarily in the extracellular space, but a fraction can pass into the
intracellular compartment [130]. DMPS removes Hg better from the kidney than DMSA. In cases of
acute poisonings with inorganic mercuric salts, DMSA is considered the drug of choice [141,144].
4.4. Penicillamine (D-2-amino-3-mercapto-3-methylbutanoic acid)
d-Penicillamine (d-2-amino-3-mercapto-3-methylbutanoic acid, Cuprimine) was introduced in the
racemic form (PA) for the treatment of Wilson disease by John Walshe [155]. It is a product of penicillin
degradation. Its structure represents a dimethylated cysteine where two methyl groups surround
the SH group and give the molecule a higher resistance than cysteine against in vivo interactions.
The d-form of penicillamine has fewer side effects than the l-form and is currently the preferred
therapeutic form [156]. Penicillamine’s distribution volume consists primarily of the extracellular
space. Accidentally, penicillamine may give rise to serious adverse effects [157]. Also, d-penicillamine
has been used as an antidote in Hg and Pb poisonings, before DMSA and DMPS were clinically
introduced [130].
4.5. Lipoic and dihydrolipoic acids
Alpha-lipoic acid ((R)-5-(1,2-Dithiolan-3-yl)pentanoic acid, LA) is an organo-sulfur compound
also known as thioctic acid. It is usually produced in the body, and it is essential for aerobic metabolism.
The reduced form of LA, called dihydrolipoic acid (DHLA), contains a pair of thiol groups. Here again,
the R-enantiomer is the biologically and therapeutically active form. DHLA has high affinity to Hg
and has been proposed as an effective Hg antidote [158,159].
4.6. MiADMSA (monoisoamyl 2, 3-dimercaptosuccinic acid)
Monoisoamyl 2, 3-dimercaptosuccinic acid (MiADMSA) is currently in development as a future
chelating agent. In contrast to DMSA and DMPS, which effectively remove extracellularly distributed
Cd [160], MiADMSA can also chelate intracellular Cd [161]. This analog of DMSA can cross
biomembranes and is more efficient than DMSA in reducing the burden of subchronic and acute arsenic
intoxications [162]. Also, MiADMSA has lower toxicity than DMSA [163]. When used together with
N-acetylcysteine, it reduces significantly oxidative stress during chelation therapy [164].
4.7. Thiocarbamates (Diethyldithiocarbamate and Derivatives)
Depending on the lipophilicity of a metal-chelator complex, chelating agents may change the
metal’s organ distribution, and thereby potentially increase its toxicity. Diethyldithiocarbamate
(DDC) was originally suggested as an efficient chelator for acute Cd intoxication, as parenteral DDC
administration decreased mortality induced by parenteral Cd in animal experiments, even at protracted
time after Cd administration [165]. In general, DDC forms highly lipophilic complexes with divalent
metal ions. Increased brain deposition caused by exposure to DDC has been documented for organic
and inorganic Hg [166], as well as for Pb [167].
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However, some derivatives of DDC with higher molecular weight appear promising in mobilizing
aged Cd deposits. Thus, N(methoxybenzyl)-Dglucamine dithiocarbamate in studies on animals
effectively reduced the retention of Cd both in organs and the entire body. This agent’s effects were
shown to be less pronounced in younger than in older animals. The highest administered Cd fraction
retained in the liver, and the strongest chelation therapy effect observed was also on liver deposits.
Mobilized Cd was almost exclusively excreted through feces [168].
5. Combination of Chelating Agents
It has been shown that DMSA, used in combination with Monensin (the sodium salt of monensic
acid, an antibiotic used in ruminant animal feeds [45]), is even more efficient than when it is used
alone, in particular in removing Pb deposited in the brain. The suggested mechanism to explain this is
that there may be a cotransport of Pb and OH ions leaving the cells, in exchange with external sodium
ions; this would promote transport of intracellular Pb to extracellular DMSA, thereby enhancing its
effectiveness [169]. Thus, Monensin acts as a shuttling agent for DMSA [118]. The combination of EDTA
and BAL was, for many years, recommended in inorganic Pb poisonings [170–172]. It is reasonable to
assume that the tightly bound Hg-ions in the brain after long-term Hg0 vapor exposure, to some extent,
can be mobilized by using minor doses of BAL as a brain-to-blood shuttle, in combination with DMPS
to promote the final elimination from the body [118]. Furthermore, a combination of MiADMSA and
DMSA may be proven more efficient than each agent alone to promote Cd mobilization, although this
metal is tightly bound to MTs intracellularly [160].
In cases with acute Hg salt poisonings, venous hemodiafiltration (CVVHDF) is suggested in
combination with DMPS. In a case reported by Dargan, a man who had severe Hg poisoning
after the ingestion of one gram mercuric sulfate in a suicide attempt, presented acute hematemesis
and deteriorated rapidly. The treatment with the combined strategy saved him. He developed
no neurological symptoms and was symptom-free five months after being 50 days under hospital
care [173].
6. Chemical Features of BAL, DMSA, DMPS, Penicillamine, Lipoic Acid, Dihydrolipoic Acid,
and their Metal Chelates
6.1. Protonation of the Thiolate Anions
In the following, we report the acidic properties of the chelating agents BAL, DMSA, DMPS,
penicillamine, lipoic acid, and dihydrolipoic acid, together with those of the simpler ligands thioglycolic
acid and thiomalic acid related to DMSA, to obtain insight into the behavior of the parent molecules.
Table 3 reports selected protonation constants of these ligands (those concerning the mercapto groups
are marked in red) together with their structure, the used acronyms, the formula, and the molecular
weights. The protonation constants are of particular importance since they determine the biological
properties of a drug, such as its solubility, absorption, cell penetration, and bioavailability. Furthermore,
protonation constants are also of primary importance in determining the speciation of the complexes
formed with the toxic metal ions of interest.
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Table 3. Protonation constants of thioglycolic acid, thiomalic acid, meso-2,3-dimercaptosuccinic acid
(DMSA), dimercaptopropane sulfonate (DMPS), penicillamine, lipoic acid, dihydrolipoic acid, and
some other simple ligands useful to characterize the acid behavior of SH ligands.
Structure Name Acronym Formula MW log K1 log K2 log K3 log K4
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Dihydrolipoic
acid
DHLA C8H16O2S2 208.343 [178] 1 .02 9.86 4.73
The protonation constants related to the SH groups are marked in red. * Determined in non-aqueous solvent,
$ determined in t is work.
6.1.1. TGA and TMA
The speciation plots f thioglycolic acid (TGA) and thiomalic acid ( ) a e repo ted in Figure 1.
In the case of TGA, the negatively charged [LH]− species with protonated m rcapto gro p is the
prevailing one at physi logical pH. In the case of TM , the [LH]2- s ies, which ha lost tw protons
from the carboxylic gr ups, is the pr vailing one.
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Figure 1. Speciation plots of TGA (top) and TMA (bottom).
6.1.2. BAL
BAL (2,3 dimercaptopropan-1-ol, dimercaprol) is a visco s oily liquid with a pungent odor of
mercaptan, density 1.23985 g/mL, solubility in water 87 g/L, or 0.7 M [179,180]. It is characterized by
two protonation constants (log K1 10.8 and log K2 8.7 obtained as the mean values among the cases
reported at 25 ◦C and 0.1 M in the IUPAC Stability Constant Database [181]. The s eciation plot is
reported in Figure 2. The completely protonated form LH2 is prevalent at pH 7.4 (95.2%) together with
the monoprotonated form (LH)− (4.8%).
Molecules 2019, 24, 3247 14 of 32
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Figure 2. Speciation plots of British anti-Lewisite (BAL).
6.1.3. DMSA
DMSA (meso-2,3-dimercaptosuccinic acid, Succimer) is a white crystalline powder with m captan
odor and tas e, water-solubility 2.43 g/L (DMSA is sparingly soluble; it m st be titra ed with alkali
to pH 5.5 to go into soluti n, i.e., it must be salified on both carboxylic gr ups, as can be seen in the
speciation plot in Figure 3), log P =−0. . It is characterized by four protonation constants, l gK1 = 12.05,
logK2 = 9.65, logK3 = 3.43, and logK4 = 2.71. Its formula and the related speciation plot are presented
in Figure 3. The form [LH2]2− that has lost both the carboxylic protons is the prevalent form at pH 7.4
(99.4%).
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Figure 3. Speciation plots of DMSA.
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Esters of DMSA, more effective than DMSA at clearing Hg and Cd from the intracellular space,
have been developed successively. Their better chelating properties are attributed to their higher
lipophilicity, favoring cell penetration. Despite the esterification of carboxylic groups, the net charge
at pH 7.4 is almost the same as that of the parent molecule, due to the resulting increased acidity of
mercapto groups (Figure 4) [174].
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Figure 4. Speciation plots of methyl-DMSA (top) and dimethyl-DMSA (bottom).
6.1.4. DMPS
DMPS (2,3-dimerca t ropane-1-sulfoni acid) is used as the sodiu t t presents as a white
crystalline powder with one molecule of crystallization water of general formula C3H7NaO3S3 · H2O,
MW 228. 6, produced in Germany by Heyl Chemisch-pharm zeutische Fabrik GmbH, with the trade
Molecules 2019, 24, 3247 16 of 32
name of Dimaval®. It has a high water solubility of 350 g/L, corresponding to a 1.54 M solution.
It is commercially available as ampules for injection (250 mg as C3H7NaO3S3 in a sterile solution
under nitrogen atmosphere to protect against oxidation) or as 100 mg capsules for oral use (always
as C3H7NaO3S3). It is characterized by two protonation constants, logK1 = 11.62 and logK2 = 8.53,
behaving in the sulfonic group as a strong acid. Its formula and the related speciation plot are presented
in Figure 5. The form [LH2]− deprotonated on the sulfonic group is the prevalent form at pH 7.4
(99.4%) [182].
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6.1.6. Lipoic an dihydrolipoic acids
Lipoic acid, (R)-5-(1,2- it iol - - l) t ic ci , known as α-lipoic acid, (LA) or thioctic acid,
appears s yellow needle-like crystals. It is reported to be v ry slightly soluble in water (0.224 g/L,
corresponding to a solution 1.16 mM).
Since no protonation constant in water solution is reported in the literature for the carboxylic acid,
we determined it at 25 ◦C and 0.1 M NaCl ionic strength through potentiometric measurements. The
lipoic acid was a reagent-grade Aldrich product, used without further purification. The operating
conditions were those generally used by our research group [184]. The solution of ligand to be titrated
was obtained by dissolving an excess of lipoic acid in 0.1 M NaCl solution in an ultrasound bath for
3 h. This solution resulted in 6.1 mM of lipoic acid, corresponding to a solubility of 1.26 g/L, about six
times greater than that reported above. The log K of protonation resulted in 4.704 (1), very similar to
the value 4.73 for DHLA found by Bonomi et al. at the same experimental conditions [178].
Dihydrolipoic acid (DHLA), 6,8-Bis(sulfanyl)octanoic acid, is the reduced form of lipoic acid. It
is freely soluble in water (103 g/L corresponding to a 0.49 M solution), it has a log P 2.24, and it is
characterized by the three protonation constants logK1 = 11.02, logK2 = 9.86, and logK3 = 4.73 at 25 ◦C
and 0.1 M ionic strength [178]. The speciation plots of lipoic acid and DHLA are reported in Figure 7.
Some general features on the results for the protonation constants of mercapto groups (Table 3) can
be remarked. In molecules with a single SH group, the log K value presents a low variability, ranging
from 9.96 for TGA to 10.35 for DPEN. There is instead a large difference in both the first (10.38 BAL,
11.35 DMPS, and 12.05 DMSA) and also the second protonation constants (8.7 BAL, 8.69 DMPS, and
9.65 DMSA) when two SH groups are present in the molecule. These differences are to a large extent
due to the different charges on the entire molecule. The solid-state structures of a number of examined
chelating agents are presented in Table S1.
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Figure 7. Speciation pl ts of Lipoic acid (top) and dihydrolipoic acid (DHLA) (bottom).
6.2. Complex Formation Reactions between Hg2+, Cd2+, and Pb2+ and Thiol Chelating Agents
As remarked in a previous work [185], the literature reports only a few data on the complex
formation equilibria between Hg2+, Cd2+, Pb2+, and the thiol chelating agents in Table 4. The literature
complex formation constants are reported in Table 4. In the same table, the corresponding pM values
are reported for each ligand–metal ion system. Irrespective of the complexation model, the pM values
permit us to develop some consideration on the general behavior of each metal ion. The speciation
plots for the systems are shown in Figure S1.
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Table 4. Complex formation constants of thioglycolic acid, thiomalic acid, DMSA, DMPS, penicillamine,
lipoic acid, dihydrolipoic acid with Hg2+, Cd2+, and Pb2+. The pM values for each system are also
reported in red.
Hg2+ Cd2+ Pb2+
Ligand Species Logβ Species Logβ Species Logβ Temp./Ion. Str. Method
TGA [186]
HgL
34.5 [187]
CdLH
11.08 [188] PbL 8.5 [186] 25, 0.1 M
NaClO4
EMF
HgL2 40.5 CdL 4.34 [187] 25, 3 M
LiClO4
gl
CdL2 6.49 [188] 25, 0.15 M gl
pM 32.9 6.00 6.95
TMA [189]
HgL
9.94 [190]
CdL
10.05 [181] PbL 10.80 [189] 25, 0.1 M
KNO3
gl
HgL2 18.07 CdL2 13.51 [190] 25, 0.2 M
KNO3
gl
Cd3L4 41.59 [181] 30, 0.007
ClO4−
gl
pM 8.24 7.78 8.90
DMSA § —- [181]
CdLH3
28.73 [191] PbL 17.4 [181] 25, 0.1 M
KCl
gl
CdLH 23.50 [191] 25, 0.1 M Spect.
CdL 17.11
pM 11.48 11.45
DMPS [192]
HgL
42.2 [193]
CdL2
28.27 [181] PbL 16.38 [192] 25, 0.1 M
NaClO4
ISE
HgL2 53.1 Cd3L3 59.9 PbL2 22.21 [193] 25, 0.2 M
KNO3
gl
Cd3L4 71.9 [181] 20, 0.1
KNO3
EMF
Cd5L6 114.3
Cd7L8 156.7
pM 37.60 13.24 12.00
[181]
HgL
39.71 [181]
CdL
17.32 [181] 20, 0.1
KNO3
EMF
CdL2H 35.19 [181] 37, 0.15
NaCl
gl
CdL2 28.22
Cd2L2 37.72
Cd3L3H 61.91
pM 34.80 12.14
DPEN [194]
HgL
37.6 [190]
CdL
11.53 [181]
PbLH
15.87 [194] 25, 0.1 M
KNO3
HgL2H 52.31 CdL2 19.64 PbL 13.12 [190] 25, 0.2 M
KNO3
gl
HgL2 43.69 Cd3L4 50.22 PbL2H 26.19 [181] 25, 0.1 M
KCl
gl
PbL2 17.7
pM 34.50 8.61 10.50
[186]
HgL
37.8 [194]
CdL
11.51 [186] 25, 0.1 M
NaClO4
gl
HgL2H 53.6 CdL2H 15.94 [194] 25, 0.1 M
KNO3
HgL2 44.50 CdL2 19.52
CdL3 22.35
pM 35.30 8.46
§ Precipitation occurs [195].
In the case of Hg complexes, apart from the pHg value 8.24 for the Hg–TMA complexes studied by
Lenz and Martell [189], the pHg values are all extremely high, regardless of the number of SH groups
in the molecule. Contrarily, the pM values of Cd2+ and Pb2+.complexes with the ligands containing
two SH binding groups are higher than those with ligands with a SH group alone. The pCd and pPb
values are lower than the corresponding pHg values of more than 20 pM units. In a work of Basinger
et al. [186], the authors stated “(a) the structural chemistry of Hg2+ complexes with thiol-containing
ligands, (b) the stability constants for such systems and (c) the relative efficacy of 29 compounds as
antidotes for Hg poisoning has been carried out to determine the structural requirements for Hg2+
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antidotes. This leads to the suggestion that instances in which two thiol groups on the same chelate
molecule are simultaneously bonded to the same Hg2+ species in a complex, water-soluble or otherwise,
are not found, and Hg2+ species bearing two sulfur donors generally have a bond angle of 180◦ or so
between these two bonds. It was hypothesized, from this, that chelating agents bearing a single SH
group might be almost as effective as Hg antidotes as those bearing two groups. Data on the stability
constants and antidotal effectiveness are presented for such structures, but in general, molecules which
do not have the potential ability to chelate are also inferior as antidotes. From the data assembled, it
would appear that the presence of a second donor group is required. Because of the lability of the
Hg-SH bond, this second site seems necessary to provide the required kinetic stability for the complex.
In the case of dithiols, the Hg may move back and forth from one sulfur donor site to another but may
not (and possibly cannot) bind firmly and simultaneously to both donor sites.”
In their potentiometric equilibrium study on the complex formation reaction between Hg2+ and
dithiol chelating agents, Rivera et al. [195] pointed out the formation of a 1:1 complex in which both
the two thiol groups were involved in coordination. In the case of DMSA, they proposed the structure
in Figure 8, as well as Aposhian et al. [125] six years later.
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Figure 8. The molecular formula of DMSA–Hg complex proposed by Rivera et al. [193].
In a work of 2004, George et al. [145] presented a study of the solution chemistry of mercuric
ions with DMSA and DMPS, employing X-ray absorption spectroscopy and density functional theory
calculations (DFT). The reported c mplexes were Hg2L2 and Hg3L3 for DMSA, and Hg2L2 for DMPS,
at 1:1 M/L ratio. With DMPS at 1:4 M/L ratio, HgL4 was also observed. Contrary to established thinking
reported above, the authors st ted that the two functional groups of the chelator molecule cannot bind
a common atom of Hg because the distance betwee the two sulfur atoms in the olecule of DMSA
or DMPS does not allow the accommodation of a linear two-coordinate S–Hg–S species (Figure 8).
Therefore, they concluded that more complex structures must be occurring with at least two DMSA or
DMPS molecules and at least two Hg atoms, and based on DFT studies; they proposed the structures
in Figure 9 in which the two coordinated species are both close to linear.
Chekmeneva et al. used differential pulse voltammetry (DPV) and electrospray ionization mass
spectrometry (ESI-MS) to the study of the binding of DMSA, DMPS, and DPEN with Hg2+ metal
ions [196]. The use of voltammetric titrations allowed obtaining a thorough picture of the complexation
schemes in a concentration range extremely low. The main formed complexes were Hg(DPEN)2,
Hg2(DMSA)2, and Hg(DMPS)2. Further minor species were also evidenced; Hg2L species for DMSA
and DMPS by DPV; HgL2, Hg2L3, Hg3L3 for DMSA; and Hg2L2, Hg2L3, Hg3L3 for DMPS by ESI-MS.
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Figure 9. Calculated structures of the two diastereomers of the smallest possible DMSA:Hg2+ complex.
The carbon atoms are depicted as dark gray, oxygen atoms as red, hydrogen atoms as white, mercury
atoms as light gray, and sulfur atoms as yellow. Reproduced from reference [144].
The system Hg-DPEN was previously studied by Koszegi-Szalai and Paal [197], who by
potentiometric methods and Raman spectroscopy showed that variously protonated Hg(DPEN)2
complexes are the dominant species in a wide range of pH, and by Leung et al. [198]. These last authors
studied the complexation of Hg2+ by DPEN using EXAFS and 199Hg NMR, giving evidence of the
formation of HgL2, and HgL3 in excess of DPEN.
The structure of the complex formed by two DHLA molecules, one Hg2+ ion, and two phenyl-Hg
groups, shown in Figure 10, presents a similar linear binding coordination mode [199].
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The linear coordination of Hg2+ is also indirectly reported by Chekmeneva et al. [200], who
remarks the formation of 1:1 and 1:2 metal:ligand complexes through DPV, and give evidence of the
more complex stoichiometries Hg2(DHLA)2, Hg(DHLA)2, Hg2(DHLA)4, and Hg4(DHLA)4 through
ESI-MS spectroscopy. The formation of polynuclear species can be explained, taking into consideration
the short distance b tween the two thiol-groups in the chelating agent. Only the p rticipation of several
ligand moieties can provide a stable lin ar conformation with two thiol groups for ach Hg2+ metal
ion. The structures presented in Table S2 for a number of Hg–SH complexes confirm the preferred
linear coordination of the Hg2+ metal ion.
In the case of Cd2+ complexes with thiol-containing ligands (Table 4), a significant difference can
be observed between the pCd values of ligands containing a single SH group (TGA 6.00, TMA 7.78,
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DPEN 8.61, 8.46) and those containing two vicinal SH groups (DMSA 11.48, DMPS 13.24, 12.14). In
this last case, the possibility of forming tetrahedral chelates favors their stability. This is confirmed
by the solid-state structures presented in Table S3. In a recent study, Jahromi et al. [201] report a
structural study of the solution equilibria between Cd2+ and DMSA and DMPS. They make use of
different techniques, X-ray absorption spectroscopy (XAS), size exclusion chromatography, and density
functional theory (DFT). The results indicate complex chemistry consistent with both DMPS and
DMSA acting as true chelators, using two thiolates for DMPS and one thiolate and one carboxylate for
DMSA [201].
A behavior analogous to that of Cd2+ is presented by Pb2+ complexes, which show a definite
difference among the ligands bearing a single SH group (TGA 6.95, TMA 8.9) and those with two
vicinal SH groups (DMSA 11.45 and DMPS 12.00), while DPEN presents an intermediate behavior
with pPb 10.5, presumably for the involvement in coordination of NH2 or COO− groups. A paper
by Gala Morales et al. [202] presented a work where cyclic voltammetry (CV) and DPV were used
to study the complex formation of Pb2+ with DMSA and DMPS. Multivariate curve resolution was
applied to voltammetric results to estimate the stoichiometries and stability constants of the formed
complexes. In both systems, the ML2 was found as the predominant species. Table S4 presents a
number of solid-state structures of Pb2+ complexes with mercapto ligands.
7. Conclusions
Based on clinical, experimental, and in vitro studies discussed in the present review, some
up-to-date recommendations can be given with regard to drugs of choice in metal intoxications with
Hg, Cd, and Pb (Table 5). The metal chelator DMSA is considerably less toxic than the classical metal
antidote BAL, and today DMSA is the recommended agent in poisonings with Pb and organic Hg. Its
toxicity is also lower than that of DMPS, although DMPS is the recommended agent in acute poisonings
with mercuric salts. We have suggested that intracellular Cd deposits and cerebral deposits of inorganic
Hg, to some extent, can be mobilized by a combination of antidotes (Table 5), but clinical experience
with such combinations are lacking. The agent MiADMSA is not yet commercially available, and its
possible use in Pb poisonings must await further research. Moreover, the clinical combination of minor
doses of BAL with DMPS in cases of Hg vapor overexposure is also insufficiently studied.
Table 5. Recommended chelation treatment in poisonings with mercury, cadmium, and lead.
Toxic Agent Recommended Chelation Treatment
Inorganic mercuric salts DMPS
Methyl mercury DMSA
Elemental mercury vapor DMPS (initially combined with BAL)
Cadmium DMSA (combined with MiADMSA)
Lead DMSA (combined with Monensin)
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